AXL and non-small cell lung carcinoma: According to a recent report, inhibition of AXL is known to contribute to overcoming drug resistance, activation of immune response and inhibition of metastasis in TNBC and NSCLC (Gjerdrum et al., 2010; Kim et al., 2019; Taniguchi et al., 2019; Wang et al., 2019; Yokoyama et al., 2019).